Teladoc Health 미래 성장

Future 기준 확인 0/6

Teladoc Health (는) 각각 연간 83.2% 및 0.9% 수익과 수익이 증가할 것으로 예상됩니다. EPS는 연간 88.3% 만큼 성장할 것으로 예상됩니다. 자기자본이익률은 3년 후 -13.2% 로 예상됩니다.

주요 정보

83.2%

수익 성장률

88.3%

EPS 성장률

Healthcare Services 수익 성장	32.4%
매출 성장률	0.9%
향후 자기자본 수익률	-13.2%
애널리스트 커버리지	Good
마지막 업데이트	29 Jan 2025

최근 미래 성장 업데이트

Teladoc Health, Inc. (NYSE:TDOC) Just Reported Third-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?

Nov 02

Recent updates

Teladoc Health, Inc. (NYSE:TDOC) Surges 40% Yet Its Low P/S Is No Reason For Excitement

Nov 26

Teladoc Health, Inc. (NYSE:TDOC) Just Reported Third-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?

Nov 02

Is Teladoc Health (NYSE:TDOC) A Risky Investment?

Oct 23

Teladoc: Double-Digit FCF Yield, Possible BetterHelp Transition

Oct 13

Teladoc Health, Inc. (NYSE:TDOC) Surges 28% Yet Its Low P/S Is No Reason For Excitement

Sep 18

Teladoc Health: Some Negative Things, But One Aspect That Makes Me Feel Positive

Sep 15

Teladoc: Prospects Are Ready For Better Health

Sep 04

Teladoc Post Q2 Earnings: Stick A Fork In This Stock - It's Nearly Done (For)

Aug 01

Teladoc's Vital Signs: Why 5x FCF Means Stable Health (Rating Upgrade)

Jul 22

Teladoc Health, Inc.'s (NYSE:TDOC) Revenues Are Not Doing Enough For Some Investors

Jul 17

Teladoc Health: Weight Loss Management Could Help

Jul 01

Would Teladoc Health (NYSE:TDOC) Be Better Off With Less Debt?

Jun 04

Teladoc: Stock Likely To Be Range Bound Until Guidance Is Revised Upwards

May 31

Teladoc: Huge Execution Problem

Apr 27

Teladoc: Improving Business Trends (Rating Upgrade)

Apr 17

Teladoc: Management Has A Lot To Prove To Gain Investor Confidence

Mar 25

Teladoc Health, Inc.'s (NYSE:TDOC) 25% Dip In Price Shows Sentiment Is Matching Revenues

Mar 10

Teladoc Health: Another Bad Quarter, Another Wave Of Capitulation

Feb 21

Teladoc Health: Weight Management Rescue

Jan 21

Teladoc Health (NYSE:TDOC) Is Carrying A Fair Bit Of Debt

Jan 15

When Should You Buy Teladoc Health, Inc. (NYSE:TDOC)?

Dec 12

Teladoc Q3: Getting Stronger (Rating Upgrade)

Nov 29

Teladoc Health, Inc.'s (NYSE:TDOC) Intrinsic Value Is Potentially 78% Above Its Share Price

Nov 22

Teladoc Was Obliterated

Oct 25

Is Teladoc Health (NYSE:TDOC) A Risky Investment?

Oct 11

Teladoc: Broken Growth Story Deteriorates Further (Rating Downgrade)

Oct 02

Teladoc Stock: A Hold Amid New Covid Wave

Sep 14

Teladoc's Technical Decline Hints At A Buying Opportunity

Aug 28

Is There An Opportunity With Teladoc Health, Inc.'s (NYSE:TDOC) 44% Undervaluation?

Aug 18

Buy Teladoc: AI Will Likely Spur Healthcare Deflation

Aug 16

Teladoc's Future: Virtual Healthcare, AI, And Valuation

Jul 28

Teladoc And Microsoft's Expanded Strategic Partnership Is A Powerful AI Combo

Jul 21

The Big Trends: New Frontiers in Healthcare

Jul 13

When Should You Buy Teladoc Health, Inc. (NYSE:TDOC)?

Jul 10

Teladoc Health: Likely To Remain Out Of Favor

Jun 26

Teladoc Health, Inc.'s (NYSE:TDOC) Revenues Are Not Doing Enough For Some Investors

Jun 25

Here's Why Teladoc Health (NYSE:TDOC) Can Afford Some Debt

May 25

Teladoc: BetterHelp Segment Margins Are Key

May 23

Are Investors Undervaluing Teladoc Health, Inc. (NYSE:TDOC) By 20%?

May 06

수익 및 매출 성장 예측

NYSE:TDOC - 애널리스트의 미래 추정치 및 과거 재무 데이터 (USD Millions )
날짜	수익	수익	잉여 현금 흐름	작전 현금	평균 애널리스트 수
12/31/2027	2,664	-92	239	386	6
12/31/2026	2,594	-149	227	349	21
12/31/2025	2,546	-157	231	348	25
12/31/2024	2,568	-990	182	302	25
9/30/2024	2,590	-982	207	338	N/A
6/30/2024	2,609	-1,006	196	333	N/A
3/31/2024	2,619	-233	200	346	N/A
12/31/2023	2,602	-220	194	350	N/A
9/30/2023	2,580	-4,002	112	285	N/A
6/30/2023	2,531	-4,018	64	243	N/A
3/31/2023	2,471	-7,054	47	234	N/A
12/31/2022	2,407	-13,660	17	189	N/A
9/30/2022	2,323	-9,860	65	207	N/A
6/30/2022	2,234	-9,871	107	221	N/A
3/31/2022	2,144	-6,904	99	180	N/A
12/31/2021	2,033	-429	130	194	N/A
9/30/2021	1,862	-812	-54	-4	N/A
6/30/2021	1,629	-763	-92	-49	N/A
3/31/2021	1,367	-655	-102	-65	N/A
12/31/2020	1,094	-485	-80	-54	N/A
9/30/2020	867	-110	59	80	N/A
6/30/2020	716	-95	46	61	N/A
3/31/2020	606	-98	19	31	N/A
12/31/2019	553	-99	19	30	N/A
9/30/2019	520	-105	4	14	N/A
6/30/2019	493	-108	2	11	N/A
3/31/2019	457	-103	-8	1	N/A
12/31/2018	418	-97	-13	-5	N/A
9/30/2018	372	-117	-22	-15	N/A
6/30/2018	330	-125	N/A	-37	N/A
3/31/2018	280	-115	N/A	-36	N/A
12/31/2017	233	-107	N/A	-34	N/A
9/30/2017	194	-77	N/A	-35	N/A
6/30/2017	157	-75	N/A	-38	N/A
3/31/2017	139	-75	N/A	-47	N/A
12/31/2016	123	-74	N/A	-52	N/A
9/30/2016	108	-75	N/A	-57	N/A
6/30/2016	96	-58	N/A	-59	N/A
3/31/2016	88	-61	N/A	-54	N/A
12/31/2015	77	-58	N/A	-47	N/A
9/30/2015	68	-50	N/A	-39	N/A
6/30/2015	59	-42	N/A	-24	N/A
3/31/2015	51	-29	N/A	-19	N/A
12/31/2014	44	-20	N/A	-11	N/A

애널리스트 미래 성장 예측

수입 대 저축률: TDOC 향후 3년 동안 수익성이 없을 것으로 예상됩니다.

수익 vs 시장: TDOC 향후 3년 동안 수익성이 없을 것으로 예상됩니다.

고성장 수익: TDOC 향후 3년 동안 수익성이 없을 것으로 예상됩니다.

수익 대 시장: TDOC 의 수익(연간 0.9% ) US 시장( 8.8% 보다 느리게 성장할 것으로 예상됩니다. 8.8% 연간).

고성장 수익: TDOC 의 수익(연간 0.9% )은 연간 20% 보다 느리게 증가할 것으로 예상됩니다.

주당 순이익 성장 예측

미래 자기자본 수익률

미래 ROE: TDOC (는) 3년 내에 수익성이 없을 것으로 예상됩니다.

성장 기업 발견

기업 분석 및 재무 데이터 현황

데이터	마지막 업데이트(UTC 시간)
기업 분석	2025/02/02 12:45
장 마감 주가	2025/01/31 00:00
수익	2024/09/30
연간 수익	2023/12/31

데이터 소스

기업 분석에 사용된 데이터는 S&P Global Market Intelligence LLC의 데이터입니다. 이 보고서를 생성하기 위해 분석 모델에 사용된 데이터는 다음과 같습니다. 데이터는 정규화되어 있으므로 소스가 제공되기까지 지연이 발생할 수 있습니다.

패키지	데이터	기간	미국 소스 예시 ^*
회사 재무	10년	손익 계산서 현금 흐름표 대차 대조표	SEC 양식 10-K SEC 양식 10-Q
애널리스트 컨센서스 추정치	+3년	재무 예측 애널리스트 목표가	애널리스트 연구 보고서 Blue Matrix
시장 가격	30년	주식 가격 배당금, 분할 및 액션	ICE 시장 데이터 SEC 양식 S-1
소유권	10년	최대 주주 내부자 거래	SEC 양식 4 SEC 양식 13D
관리	10년	리더십 팀 이사회	SEC 양식 10-K SEC 양식 DEF 14A
주요 개발 사항	10년	회사 공지 사항	SEC 양식 8-K

* 미국 증권의 경우, 미국 외 지역의 규제 양식 및 출처가 사용된 예입니다.

명시되지 않는 한 모든 재무 데이터는 1년을 기준으로 하지만 분기별로 업데이트됩니다. 이를 후행 12개월(TTM) 또는 최근 12개월(LTM) 데이터라고 합니다. 여기에서 자세히 알아보세요.

분석 모델 및 눈송이

이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 Github 페이지에서 확인할 수 있으며, 보고서 사용 방법에 대한 가이드와 튜토리얼도 유튜브에서 확인할 수 있습니다.

Simply 월스트리트 분석 모델을 설계하고 구축한 세계적인 수준의 팀에 대해 알아보세요.

산업 및 부문 메트릭

업계 및 섹션 지표는 Simply Wall St에서 6시간마다 계산되며, 자세한 내용은 확인할 수 있습니다.

애널리스트 출처

Teladoc Health, Inc. 44 애널리스트 중 25 애널리스트가 보고서의 입력 자료로 사용된 매출 또는 수익 추정치를 제출했습니다. 애널리스트의 제출 자료는 하루 종일 업데이트됩니다.

분석가	교육기관
null null	Argus Research Company
Vikram Kesavabhotla	Baird
Matthew Gillmor	Baird

Teladoc Health 미래 성장

Future 기준 확인 0/6

주요 정보

최근 미래 성장 업데이트

Teladoc Health, Inc. (NYSE:TDOC) Just Reported Third-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?

Teladoc Health, Inc. Provides Earnings Guidance for the Fourth Quarter and Full Year of 2024

Consensus EPS estimates fall by 394%

Price target decreased by 11% to US$14.45

Teladoc Health, Inc. Provides Earnings Guidance for the Second Quarter and Full Year of 2024

Price target decreased by 7.5% to US$18.42

Recent updates

Is Teladoc Health (NYSE:TDOC) Using Too Much Debt?

Teladoc: Minimal Growth Left As More Healthcare Players Leave/Diversify

Teladoc: Attractive Valuation, But The Narrative Stalls

Teladoc: Maybe This Goose Isn't Cooked Yet (Rating Upgrade)

Teladoc Health, Inc. (NYSE:TDOC) Surges 40% Yet Its Low P/S Is No Reason For Excitement

Teladoc Health Expands AI Capabilities for Hospitals and Health Systems with Advanced Virtual Sitter Solution

Chief People Officer notifies of intention to sell stock

Teladoc Health, Inc. (NYSE:TDOC) Just Reported Third-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?

Teladoc Health, Inc. Provides Earnings Guidance for the Fourth Quarter and Full Year of 2024

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

Is Teladoc Health (NYSE:TDOC) A Risky Investment?

Teladoc Health, Inc. to Report Q3, 2024 Results on Oct 30, 2024

Insider notifies of intention to sell stock

Teladoc: Double-Digit FCF Yield, Possible BetterHelp Transition

Teladoc Health, Inc. (NYSE:TDOC) Surges 28% Yet Its Low P/S Is No Reason For Excitement

Teladoc Health: Some Negative Things, But One Aspect That Makes Me Feel Positive

Teladoc Health, Inc. Appoints Joseph Catapano as its Senior Vice President and Chief Accounting Officer

Teladoc: Prospects Are Ready For Better Health

Consensus EPS estimates fall by 394%

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

Price target decreased by 11% to US$14.45

Teladoc Post Q2 Earnings: Stick A Fork In This Stock - It's Nearly Done (For)

Teladoc's Vital Signs: Why 5x FCF Means Stable Health (Rating Upgrade)

Teladoc Health, Inc. to Report Q2, 2024 Results on Jul 31, 2024

Teladoc Health, Inc.'s (NYSE:TDOC) Revenues Are Not Doing Enough For Some Investors

Teladoc Health, Inc.(NYSE:TDOC) dropped from Russell 1000 Dynamic Index

Teladoc Health: Weight Loss Management Could Help

Teladoc Health, Inc. Releases New Data from Two Studies

Teladoc Health, Inc. Appoints Charles Divita, III as Director

Would Teladoc Health (NYSE:TDOC) Be Better Off With Less Debt?

Teladoc: Stock Likely To Be Range Bound Until Guidance Is Revised Upwards

Robbins Geller Rudman & Dowd LLP Announces Class Action Lawsuit against Teladoc Health, Inc

Teladoc: Huge Execution Problem

Teladoc Health, Inc. Provides Earnings Guidance for the Second Quarter and Full Year of 2024

First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Price target decreased by 7.5% to US$18.42

Teladoc: Improving Business Trends (Rating Upgrade)

Teladoc Health, Inc. to Report Q1, 2024 Results on Apr 25, 2024

Teladoc Health, Inc., Annual General Meeting, May 23, 2024

Teladoc Health, Inc. Announces Chief Executive Officer Changes

Teladoc: Management Has A Lot To Prove To Gain Investor Confidence

Teladoc Health, Inc.'s (NYSE:TDOC) 25% Dip In Price Shows Sentiment Is Matching Revenues

CEO & Director exercised options and sold US$780k worth of stock

Price target decreased by 9.6% to US$20.84

No longer forecast to breakeven

Teladoc Health, Inc. Provides Earnings Guidance for the First Quarter and Full Year of 2024

Teladoc Health: Another Bad Quarter, Another Wave Of Capitulation

No longer forecast to breakeven

Teladoc Health, Inc. to Report Q4, 2023 Results on Feb 20, 2024

Teladoc Health: Weight Management Rescue

Teladoc Health (NYSE:TDOC) Is Carrying A Fair Bit Of Debt

Forecast to breakeven in 2026

Independent Director notifies of intention to sell stock

When Should You Buy Teladoc Health, Inc. (NYSE:TDOC)?

Insufficient new directors

Teladoc Q3: Getting Stronger (Rating Upgrade)

Teladoc Health, Inc.'s (NYSE:TDOC) Intrinsic Value Is Potentially 78% Above Its Share Price

Teladoc Health, Inc. Announces Resignation of Claus T. Jensen, PhD as Chief Innovation Officer Effective December 1, 2023

Insider notifies of intention to sell stock

New minor risk - Shareholder dilution

Third quarter 2023 earnings: EPS exceeds analyst expectations

Teladoc Health, Inc. Provides Earnings Guidance for the Fourth Quarter and Full Year Ending December 31, 2023

Teladoc Was Obliterated

Teladoc Health, Inc. to Report Q3, 2023 Results on Oct 24, 2023

Is Teladoc Health (NYSE:TDOC) A Risky Investment?

Teladoc: Broken Growth Story Deteriorates Further (Rating Downgrade)

Teladoc Health, Inc. Appoints Eric Evans to Board of Directors

Teladoc Stock: A Hold Amid New Covid Wave

Teladoc's Technical Decline Hints At A Buying Opportunity